{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:25:50Z","timestamp":1741152350434,"version":"3.38.0"},"reference-count":74,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:p> Plant extracts of the European mistletoe (MTE), Viscum album, the most widely used cancer treatment in Germany, have been used in European countries as sole intervention or as adjunct to conventional cancer therapies for more than 80years. Preclinical data suggest immunostimulatory and cytotoxic effects of MTE. While the clinical efficacy of MTE in cancer is being investigated, toxicity and potential interactions of MTE with standard chemotherapeutic agents are unknown. Gemcitabine is an approved antimetabolite chemotherapeutic agent effective as single agent in patients with solid tumors (ST). The documented metabolism and pharmacokinetics of gemcitabine make this agent well suited for the study of botanical-chemotherapy drug interactions (BDIA) in cancer. Based on reports of altered drug metabolism associated with botanical preparations, research into BDIA has intensified. The phase I, 2-stage, dose-escalation study outlined here will test MTE with gemcitabine as a paradigm for the phase I investigation of botanical-drug combination treatments in patients with advanced ST. The protocol including the following components has been reviewed and approved by the National Cancer Institute Institutional Review Board (IRB), the National Naval Medical Center IRB, and the Navy Clinical Investigation Program (study 02-074): (1) use of a standardized MTE, approved by the Food and Drug Administration for investigational use; (2) independent verification of key MTE components considered biologically active; (3) identification of contaminants and adulterants; (4) pharmacokinetics of gemcitabine and its principal metabolites before and upon exposure to MTE; (5) safety and toxicity data collection; (6) assays of plasma ML antibody production in vivo; and (7) pharmacodynamic studies of the botanical-drug combination. <\/jats:p>","DOI":"10.1177\/1534735403259061","type":"journal-article","created":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T00:41:30Z","timestamp":1082594490000},"page":"345-352","source":"Crossref","is-referenced-by-count":11,"title":["Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy"],"prefix":"10.1177","volume":"2","author":[{"given":"Patrick J.","family":"Mansky","sequence":"first","affiliation":[{"name":"Office of the Scientific Director for Clinical Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, 8 West Drive, Quarters 15-B1, MSC 2669, Bethesda, MD 20892-2669."}]},{"given":"Jean","family":"Grem","sequence":"additional","affiliation":[]},{"given":"Dawn B.","family":"Wallerstedt","sequence":"additional","affiliation":[]},{"given":"Brian P.","family":"Monahan","sequence":"additional","affiliation":[]},{"given":"Marc R.","family":"Blackman","sequence":"additional","affiliation":[]}],"member":"179","published-online":{"date-parts":[[2003,12,1]]},"reference":[{"key":"atypb1","unstructured":"1. Steiner R. Geisteswissenschaft und Medizin. 6th ed. Dornach: Rudolf Steiner Verlag; 1985."},{"key":"atypb2","unstructured":"2. Kiene H. Klinische Studien zur Misteltherapie karzinomatoeser Erkrankungen, Eine Uebersicht. Therapeutikon. 1990;3:347-353."},{"key":"atypb3","unstructured":"3. Hauser SP. Iscador-Mistelpraeparat zur Krebsbekaempfung Dokumentation Nr. 10. Schweiz Rundschau Med Prax. 1988;77(4):69-74."},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0944-7113(11)80073-5"},{"key":"atypb5","unstructured":"5. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7:57-66, 68-72, 74-56, passim."},{"key":"atypb6","unstructured":"6. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R. A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun. 1995;14:295-304."},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"7. Stein G, Berg PA. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol. 1994;47(1):33-38.","DOI":"10.1007\/BF00193475"},{"key":"atypb8","unstructured":"8. Rentea R, Lyon E, Hunter R. Biologic properties of Iscador: a Viscum album preparation I. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Lab Invest. 1981;44(1):43-48."},{"key":"atypb9","unstructured":"9. Beuth J, Ko HL, Tunggal L, et al. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo. 1993;7:407-410."},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.3109\/08820139309063421"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(87)90095-6"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1159\/000226342"},{"key":"atypb13","doi-asserted-by":"crossref","unstructured":"13. Samtleben RHT, Hostanska K. Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed. Immunomodulatory Agents From Plants. Basel, Switzerland: Birkhauser Verlag; 1999:223-241.","DOI":"10.1007\/978-3-0348-8763-2_9"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)35897-6"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199704001-00015"},{"key":"atypb16","doi-asserted-by":"crossref","unstructured":"16. Stein GM, Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs. 1997; 8(suppl 1):S39-S42.","DOI":"10.1097\/00001813-199704001-00009"},{"key":"atypb17","unstructured":"17. Gabius HJ, Andre S, Kaltner H, Siebert HC, von der Lieth CW, Gabius S. [The mistletoe myth\u2014claims, reality and provable perspectives]. Z Arztl Fortbild (Jena).1996;90:103-110."},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1159\/000226417"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2825(20001212)14:6<255::AID-JCLA1>3.0.CO;2-J"},{"key":"atypb20","unstructured":"20. Elsasser-Beile U, Lusebrink S, Grussenmeyer T, Wetterauer U, Schultze-Seemann W. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneimittelforschung. 1998;48:1185-1189."},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(96)04401-1"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1159\/000069428"},{"key":"atypb23","unstructured":"23. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to betagalactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 1990;50:3322-3326."},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.3109\/08923970009016433"},{"key":"atypb25","unstructured":"25. Bussing A, Stein GM, Pfuller U, Schietzel M. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes. Anticancer Res. 1999;19:1785-1790."},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1177\/030089169307900116"},{"key":"atypb27","unstructured":"27. Weber K, Mengs U, Schwarz T, Becker H, Lentzen H. Stimulation of neutropoiesis by a special standardized mistletoe preparation after cyclophosphamide chemotherapy in mice. Arzneimittelforschung. 1996;46:1174-1178."},{"key":"atypb28","doi-asserted-by":"crossref","unstructured":"28. Savoie A, Lavastre V, Pelletier M, Hajto T, Hostanska K, Girard D. Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis. J Leukoc Biol. 2000;68:845-853.","DOI":"10.1189\/jlb.68.6.845"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1007\/BF01649034"},{"key":"atypb30","unstructured":"30. Stein GM, Berg PA. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Res. 1999;4:169-177."},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(98)00301-2"},{"key":"atypb32","unstructured":"32. Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res. 2000;20:2073-2076."},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00360-9"},{"key":"atypb34","unstructured":"34. Eggermont AM KU, Ruiter DJ, Suciu S. European Organization of Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. Paper presented at: American Society of Clinical Oncology Annual Meeting; 2001; San Francisco."},{"key":"atypb35","unstructured":"35. Heiny BM, Albrecht V, Beuth J. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res. 1998;18:583-586."},{"key":"atypb36","unstructured":"36. Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res. 1994;14:1339-1342."},{"key":"atypb37","doi-asserted-by":"crossref","unstructured":"37. Friess H, Buchler M, Ebert M, Malfertheiner P, Dennler HJ, Beger HG. Treatment of advanced pancreatic cancer with high-dose octreotide. Int J Pancreatol. 1993;14:290-291.","DOI":"10.1007\/BF02784939"},{"key":"atypb38","doi-asserted-by":"crossref","unstructured":"38. Gorter RW, van Wely M, Reif M, Stoss M. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern Ther Health Med. 1999;5(6):37-44, 47-38.","DOI":"10.1097\/00045391-199901000-00006"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161150-00002"},{"key":"atypb40","unstructured":"40. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-2194."},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/73.6.1101"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600671050"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1016\/S1086-5802(16)31280-3"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1331\/154434503321831148"},{"key":"atypb45","unstructured":"45. Shohet D, Wills RB, Stuart DL. Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie. 2001;56:860-863."},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1081\/DDC-100105173"},{"key":"atypb47","unstructured":"47. Guns ES, Goldenberg SL, Brown PN. Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol. 2002;9:1684-1688; discussion, 1689."},{"key":"atypb48","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.17.1261"},{"key":"atypb49","unstructured":"49. Laboratories LR. Gemcitabine hydrochloride LY 188011 Clinical Investigator\u2019s Brochure. Nov 3, 1994."},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1527"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.20.1530"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.1007\/BF00873232"},{"key":"atypb53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1535"},{"key":"atypb54","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010600"},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.11.3394"},{"key":"atypb56","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008364327684"},{"key":"atypb57","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0284"},{"key":"atypb58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.310"},{"key":"atypb59","unstructured":"59. Begbie SD, Hui R, Levi JA, et al. Initial experience with gemcitabine for non-small cell lung cancer in Australia. Proc Annu Meet Am Soc Clin Oncol. 1995; 14:A1172-A1172."},{"key":"atypb60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"atypb61","doi-asserted-by":"crossref","unstructured":"61. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002; 62(1):2-8.","DOI":"10.1159\/000048240"},{"key":"atypb62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.12.3441"},{"key":"atypb63","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200109000-00002"},{"key":"atypb64","unstructured":"64. Goedhals L. BWR. A phase II study of gemcitabine in advanced cervix carcinoma: final data; 1996."},{"key":"atypb65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.491"},{"key":"atypb66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.3.406"},{"key":"atypb67","doi-asserted-by":"crossref","unstructured":"67. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2\u2019,2\u2019-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev. 1993;19:45-55.","DOI":"10.1016\/0305-7372(93)90026-N"},{"key":"atypb68","doi-asserted-by":"publisher","DOI":"10.1007\/BF00874440"},{"key":"atypb69","doi-asserted-by":"publisher","DOI":"10.1007\/BF00877241"},{"key":"atypb70","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.382"},{"key":"atypb71","unstructured":"71. Kassem B, Miketic LM, Landreneau RJ. Phase I study of gemcitabine given weekly as short infusion. Proc Am Soc Clin Oncol. 1995;14:383-383."},{"key":"atypb72","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199605000-00017"},{"key":"atypb73","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008487932384"},{"key":"atypb74","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005817024382"}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735403259061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735403259061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:36:59Z","timestamp":1741073819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1534735403259061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1177\/1534735403259061"],"URL":"https:\/\/doi.org\/10.1177\/1534735403259061","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"type":"print","value":"1534-7354"},{"type":"electronic","value":"1552-695X"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}